简介：AIMTo评估热门non-steroidal的预防管理的功效在糖尿病的病人的有斑点的浮肿追随者奔流外科上的反煽动性的药(NSAID)，并且在NSAID的类型之间比较(ketorolactromethamine0.4%并且nepafenac0.1%).METHODSGroup(控制)1作为一个安慰剂组接待了人工的眼泪代用品，(nepafenac)组2收到了热门nepafenac(ketorolac)0.1%，和组3收到了热门ketorolactromethamine0.4%。病人们在完成一个以后手术后地被检查为评估似胞的有斑点的浮肿(CME)的星期，一个月，二个月和三月间隔开发。主要学习结果在与光连贯地形学(10月)测量的中央有斑点的厚度(CMT)正在完成最好改正的视觉尖酸(BCVA)和变化76个病人的.RESULTSEighty眼睛在这研究被包括。BCVA在第三个月显示出统计上重要的差别手术后列在后面在上面在控制组和NSAID组(P=0.04)之间。在开始从的所有情况中的CMT有增加手术后第一个星期直到第三个月。CMT显示出控制组和NSAID组之间的统计上重要的差别从手术后第一个月直到第三个月(P=0.008，0.027，0.004)。在BCVA和外科手术前的10月CMT.CONCLUSIONProphylacticnepafenac和ketorolac组之间没有统计上重要的差别，手术后的NSAID可以在在跟随奔流外科的糖尿病的眼睛减少CME的频率和严厉有一个角色。

简介：AIM:Todeterminereallifeclinicaloutcomesinpoorlyresponsiveandtreatment-naveneovascularage-relatedmaculardegeneration(nvAMD)patientsusingbimonthlyfixeddosingafliberceptregimen.METHODS:Thiswasaretrospectivestudyof165eyeswithnvAMDstartedonafliberceptatSouthamptonEyeUnitbetweenJune2013andJune2014.Patientswereeitherswitchedfromprorenata(PRN)ranibizumab/bevacizumabduetopoorresponse(107eyes),ortreatment-nave(58eyes).Patientsinitiallyreceived3-monthlyintravitrealafliberceptinjectionsfollowedby2-monthlyfixeddoses.Clinicvisitswerescheduledatmonth0,4,10and12.Meanchangeinbest-correctedvisualacuity(BCVA)andcentralretinalthickness(CRT)frombaselinewereassessedusingtheWilcoxonsignedranktest.TheproportionofpatientsmaintainingBCVA(<15lettersloss)at12mowasalsoevaluated.RESULTS:MeanBCVAchangeatmonth12was+3.29and+4.67lettersintheswitchedandnaveafliberceptgroupsrespectively(P<0.01).BCVAwasmaintainedin95.3%ofswitchedand96.6%ofnavepatients.CRTatmonth12showedadecreaseof-6.16μmintheswitchedgroupand-35.36μminthenavegroup(P<0.01).Patientspreviouslytreatedwithranibizumab/bevacizumabhadonaveragereceived7.4ranibizumab/bevacizumabinjectionsover12.6mo,attending10clinicvisits.Thefixeddosingafliberceptregimenrequiredanaverageof7.1injections(navegroup),7.5injections(switchedgroup)and4clinicvisitsperyear.CONCLUSION:Fixedbimonthlyafliberceptiseffectiveinbothtreatment-naveandpoorlyresponsivenvAMDpatients.Adoptingafixeddosingregimencanreducepatientburdenwithoutcompromisingonoutcomes.

简介：

简介：AIM:Toinvestigatetheefficacyandsafetyofkryptonlaserperipheraliridoplasty(LPIP)forChinesepatientswithprimaryangleclosure(PAC)orprimaryangle-closureglaucoma(PACG)statuspostlaseriridotomyinreversingthepositiveresultsofthedarkroomprovocativetest(DRPT).METHODS:Thisstudywasprospective,noncomparative,interventionalcaseseries.Thirty-threepatients(thirty-eighteyes)withPACorPACGstatuspostpatentlaseriridotomyandmaintainednormalintraocularpressure(IOP)butwithpositiveDRPTresultswereenrolled.AllthesubjectsweretreatedwithkryptonLPIP.DRPTwasrepeatedafterkryptonLPIP.ResultsofDRPTwererecorded.Thevisualacuity,IOPandgonioscopywereanalyzedbeforeandafterkryptonLPIP.Aminimumtimelimitforfollow-upwas6mo.RESULTS:Thirty-threepatients(thirty-eighteyes)werefollowedfor17.7±8.37mo(range7-41mo)afterLPIP.PositiveresultsofDRPTdecreasedfrom38eyesto9eyes(23.7%)afterLPIP.Peripheralanteriorsynechiaeofanglein34of38eyes(89.5%)remainedunchangedatdynamicgonioscopythroughoutthefollow-upperiodafterLPIP.CONCLUSION:LPIPdecreasedpositiveratesoftheDRPTsignificantly.ThemechanismmaybethatLPIPminimizedcontactbetweentheperipheralirisandtrabecularmeshwork,whichisakeyfactorfordevelopingperipheralanteriorsynechiae.

简介：